Did you find what you are/were looking for
?
If not, read below and browse through other relevant pages for similar market research
reports OR get in touch with us through the form/contact info in your right navigation
panel and we’ll share relevant market report titles for you to explore.
- Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma
Report SummaryGBI Research, the leading business intelligence provider, has released its latest research Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning T...
- Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for success
IntroductionThe urinary incontinence drug market has been displaying strong growth from 2005-09 owing to the uptake of new products driven by large marketing campaigns. Promotional efforts will remain integral to the success of ...
- Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales
IntroductionGrowth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster products are due to undergo patent expiry over the forecast period and the loss of their branded sales will n...
- Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options
IntroductionDatamonitor forecasts the inflammatory bowel disease market to become increasingly competitive with the anticipated launch of seven new products, spanning five drug classes from 2010 to 2019. These therapies are...
- Epigenetic Drug & Diagnostic Pipelines: DNA Methylation, HDAC Inhibitors, and Emerging New Targets Report
Epigenetics is a rapidly growing field with promising implications for treatment of cancer and potentially other diseases. Research interest in epigenetics has exploded in recent years, and considerable ...
- Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth
IntroductionSmall molecule targeted therapies represent a highly lucrative class of anticancer therapies with 12 drugs currently approved for various tumor types. This promise of high commercial rewards has driven considera...
- Opportunities in Orphan Drugs: Strategies for developing maximum returns from niche indications
The US government introduced the Orphan Drugs Act (ODA) in 1983 as a means to provide incentives to drug developers so that they would develop tr...
- Pipeline Insight: Endometriosis - New therapies near market while more innovative targets still needed
IntroductionEndometriosis is a common yet poorly understood gynecological disease that affects women of reproductive age. Symptoms include severe chronic pelvic pain and infertility. Endometriosis affects over 17 million wo...
- Commercial Insight: Molecular Targeted Cancer Therapies
IntroductionMolecular targeted cancer therapies are the biggest and fastest growing class of cancer drugs in terms of sales. As growth of revenues from cytotoxic therapies and antihormonal therapies has slowed and many...
- Pipeline Insight: Prostate Cancer Molecular targeted therapies will fulfill unmet needs in castration-resistant disease
IntroductionIncidence of prostate cancer in the seven major markets will be just over 422,000 in 2009, indicating high patient potential for drug developers to invest in. There are currently 136 agents in development for prostate can...